At-home Leqembi auto-injector now available

Clinical takeaway: For appropriate patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, clinicians may now initiate Leqembi Iqlik at home after appropriate education. Before treatment, assess amyloid-related imaging abnormality (ARIA) risk, obtain a baseline brain MRI, perform recommended ApoE ε4 testing, and plan ongoing MRI monitoring.

Eisai and Biogen announced that Leqembi Iqlik (lecanemab-irmb) is now available in the US for initiation therapy in adults with early Alzheimer’s disease, defined as mild cognitive impairment or mild dementia due to the disease.

The initiation regimen is 500 mg subcutaneously once weekly, administered as two consecutive 250-mg autoinjector injections. Each injection takes approximately 15 seconds. After 18 months of intravenous or subcutaneous treatment, patients may receive maintenance therapy with Leqembi Iqlik 360 mg once weekly. Patients can transition between subcutaneous and intravenous administration during treatment.

The at-home option may reduce infusion-center visits and associated healthcare-resource use. Eisai and Biogen are offering patient and caregiver education, injection-training materials, treatment-tracking tools, specialty-pharmacy support, and financial assistance for eligible uninsured patients.

The safety profile of subcutaneous Leqembi was similar to that of intravenous treatment, although localized injection reactions may occur. Leqembi carries a boxed warning for ARIA, including potentially serious or fatal events. ApoE ε4 homozygotes have a higher ARIA risk. Continued clinical vigilance and scheduled MRI monitoring remain necessary regardless of the administration route.

Source: Eisai Co., Ltd. and Biogen Inc. (2026 Aug 25). LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease